

## Supplementary Online Content

Pursnani A, Massaro JM, D'Agostino RB, O'Donnel CJ, Hoffmann U. Guideline-based statin eligibility, coronary artery calcification, and cardiovascular events. *JAMA*. doi:10.1001/jama.2015.7515

**eTable 1.** Identification of Incident CVD by Statin Eligibility (Excluding Subjects With Diabetes Mellitus and Those With LDL>190): Observed Event Rates and Hazards Ratios Stratified by Statin Allocation Recommendation According to 2004 ATP III Versus 2013 ACC/AHA Guidelines

**eTable 2.** Identification of Incident CVD by Statin Eligibility (Stratified by Offspring Cohort and 3rd Generation Cohort): Observed Event Rates and Hazards Ratios Stratified by Statin Allocation Recommendation According to 2004 ATP III Versus 2013 ACC/AHA Guidelines

**eTable 3.** Baseline Characteristics of Intermediate Risk Subgroup (FRS 6%-20%)

**eTable 4.** Identification of Incident CVD by Statin Eligibility With CAC=0 Becoming Ineligible for Statin Criterion

**eTable 5.** Identification of Incident CVD by Statin Eligibility (Excluding Participants With Incomplete History Regarding Family History of Premature CHD): Observed Event Rates and Hazards Ratios Stratified by Statin Allocation Recommendation According to 2004 ATP III Versus 2013 ACC/AHA Guidelines

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable 1.** Identification of Incident CVD by Statin Eligibility (Excluding Subjects With Diabetes Mellitus and Those With LDL>190): Observed Event Rates and Hazards Ratios Stratified by Statin Allocation Recommendation According to 2004 ATP III Versus 2013 ACC/AHA Guidelines

	Endpoint	Incident CVD		
	<b>N events/ Sample Size</b>	64/2291 (2.8%)		
	<b>Median Years F/up (IQR)</b>	9.4 yrs (8.1-10.1)		
		<b>N events/ Sample Size</b>	<b>HR (95% CI)</b>	<b>P value</b>
<b>2004 ATP</b>	<b>Statin-eligible</b>	<b>7.4%</b> (17/231)	<b>3.5</b> (2.0-6.0)	<.001
	<b>Not Statin-eligible</b>	<b>2.3%</b> (47/2060)	Ref	--
<b>2013ACC</b>	<b>Statin-eligible</b>	<b>6.1%</b> 49/799	<b>6.6</b> (3.7-11.7)	<.001
	<b>Not Statin-eligible</b>	<b>1.0%</b> 15/1492	Ref	--
		<b>P-value (HR<sub>2004</sub> vs HR<sub>2013</sub>)</b>		<.004

**eTable 2.** Identification of Incident CVD by Statin Eligibility (Stratified by Offspring Cohort and 3<sup>rd</sup> Generation Cohort): Observed Event Rates and Hazards Ratios Stratified by Statin Allocation Recommendation According to 2004 ATP III Versus 2013 ACC/AHA Guidelines

	Endpoint	Incident CVD - Offspring			Incident CVD - 3 <sup>rd</sup> Generation		
	<b>N events/ Sample Size</b>	48/982 (4.9%)			26/1453 (1.8%)		
	<b>Median Years F/up (IQR)</b>	9.1 yrs (8.0-10.1)			9.6 yrs (8.2-10.2)		
		<b>N events/ Sample Size</b>	<b>HR (95% CI)</b>	<b>P value</b>	<b>N events/ Sample Size</b>	<b>HR (95% CI)</b>	<b>P value</b>
<b>2004 ATP</b>	<b>Statin- eligible</b>	<b>8.6%</b> (18/209)	<b>2.3</b> (1.3-4.2)	.005	<b>4.3%</b> (6/139)	<b>3.0</b> (1.2-7.6)	.017
	<b>Not Statin- eligible</b>	<b>3.9%</b> (30/773)	Ref	--	<b>1.5%</b> (20/1314)	Ref	
<b>2013ACC</b>	<b>Statin- eligible</b>	<b>7.6%</b> 44/576	<b>8.4</b> (3.0- 23.3)	<.001	<b>4.1%</b> (15/365)	<b>4.3</b> (2.0-9.4)	<.001
	<b>Not Statin- eligible</b>	<b>1.0%</b> 4/406	Ref	--	<b>1.0%</b> (11/1088)	Ref	
		<b>P-value (HR<sub>2004</sub> vs HR<sub>2013</sub>)</b>		.007	<b>P-value (HR<sub>2004</sub> vs HR<sub>2013</sub>)</b>		.132

**eTable 3.** Baseline Characteristics of Intermediate Risk Subgroup (FRS 6%-20%)

<b>Number of Participants</b>	<b>Total (n=918)</b>	<b>No Incident CVD (n= 882)</b>	<b>Incident CVD (n= 36)</b>
Age (mean years +/-SD)	54.7 +/- 8.5	54.5 +/- 8.5	57.7 +/- 7.2
Female, n(%)	312 (34.0)	299 (33.9)	13 (36.1)
Traditional Risk Factors, n(%)			
Hypertension	377 (41.1)	361 (40.9)	16 (44.4)
Smoking	151 (16.4)	142 (16.1)	9 (25.0)
Diabetes Mellitus	62 (6.8)	60 (6.8)	2 (5.6)
Family History of Premature CHD	185 (25.1)	176 (24.9)	9 (30.0)
Lipids			
Total Cholesterol (mean mg/dl +/-SD)	210 +/- 34	210 +/- 34	205 +/-28
LDL (mean mg/dl +/-SD)	133 +/- 31	134 +/- 31	130 +/-26
HDL (mean mg/dl +/-SD)	47 +/- 13	47 +/- 14	47 +/-13
Anti-hypertensive medication (%)	195 (21.2)	187 (21.2)	8 (22.2)
Framingham Risk Score (mean+/-SD)	10.2 +/- 3.4	10.1 +/-3.4	12.0 +/-3.8
CAC score (mean+/-SD)	147 +/- 399	137 +/- 387	407 +/-571
CAC score (median, quartiles)	9.8 (0-113)	7.6 (0-96.2)	230 (55-473)
CAC > 0 (%)	569 (62.0)	537 (60.9)	32 (88.9)

**eTable 4.** Identification of Incident CVD by Statin Eligibility With CAC=0 Becoming Ineligible for Statin Criterion

	Endpoint	Incident CVD			Incident CVD CAC=0 Becomes Statin Ineligible		
	<b>N events/ Sample Size</b>	74/2435 (3.0%)			74/2435 (3.0%)		
	<b>Median Years F/up (IQR)</b>	9.4 yrs (8.1-10.1)			9.4 yrs (8.1-10.1)		
		<b>N events/ Sample Size</b>	<b>HR (95% CI)</b>	<b>P value</b>	<b>N events/ Sample Size</b>	<b>HR (95% CI)</b>	<b>P value</b>
<b>2004 ATP</b>	<b>Statin- eligible</b>	<b>6.9%</b> (24/348)	<b>3.1</b> (1.9-5.0)	<.001	<b>9.2%</b> (22/238)	<b>4.3</b> (2.6-7.0)	<.001
	<b>Not Statin- eligible</b>	<b>2.4%</b> (50/2087)	Ref	--	<b>2.4%</b> (52/2197)		
<b>2013 ACC</b>	<b>Statin- eligible</b>	<b>6.3%</b> 59/941	<b>6.8</b> (3.8- 11.9)	<.001	<b>8.5%</b> (54/635)	<b>8.4</b> (.5.0- 13.9)	.006
	<b>Not Statin- eligible</b>	<b>1.0%</b> 15/1494	Ref	--	<b>1.1%</b> (20/1800)		
		<b>P-value (HR<sub>2004</sub> vs HR<sub>2013</sub>)</b>		<.001	<b>P-value (HR<sub>2004</sub> vs HR<sub>2013</sub>)</b>		.001

**eTable 5.** Identification of Incident CVD by Statin Eligibility (Excluding Participants With Incomplete History Regarding Family History of Premature CHD): Observed Event Rates and Hazards Ratios Stratified by Statin Allocation Recommendation According to 2004 ATP III Versus 2013 ACC/AHA Guidelines

	Endpoint	Incident CVD		
	<b>N events/ Sample Size</b>	63/1984 (3.2%)		
	<b>Median Years F/up (IQR)</b>	9.4 yrs (8.2-10.2)		
		<b>N events/ Sample Size</b>	<b>HR (95% CI)</b>	<b>P value</b>
<b>2004 ATP</b>	<b>Statin-eligible</b>	<b>6.9%</b> (24/348)	<b>3.1</b> (1.9-5.2)	<.001
	<b>Not Statin-eligible</b>	<b>2.4%</b> (39/1636)	Ref	--
<b>2013ACC</b>	<b>Statin-eligible</b>	<b>6.4%</b> 52/811	<b>7.5</b> (3.9-14.4)	<.001
	<b>Not Statin-eligible</b>	<b>0.9%</b> 11/1173	Ref	--
		<b>P-value (HR<sub>2004</sub> vs HR<sub>2013</sub>)</b>		.009